close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Tectonic Therapeutic

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic to Participate in September Investor Conferences
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic Joins Russell 3000® Index
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic to Participate in March Investor Conferences
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Announces $185 Million Private Placement
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic to Participate in September Investor Conferences
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
From Tectonic Therapeutic
Via GlobeNewswire
Tickers TECX
Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million
From Tectonic Therapeutic
Via Business Wire
Tickers TECX
Tectonic Therapeutic Strengthens Leadership Team
From Tectonic Therapeutic
Via Business Wire
Fierce Biotech Names Tectonic Therapeutic as One of Its “Fierce 15” Biotech Companies of 2021
From Tectonic Therapeutic
Via Business Wire
Tectonic Therapeutic Named an “Endpoints 11” Winner
From Tectonic Therapeutic
Via Business Wire
Tectonic Therapeutic Appoints Marcella Ruddy, MD as Chief Medical Officer
From Tectonic Therapeutic
Via Business Wire
Tectonic Therapeutic Appoints Peter McNamara, PhD Senior Vice President, Head of Research
From Tectonic Therapeutic
Via Business Wire
Tectonic Therapeutic Launches with $80 Million Series A Financing to Transform the Discovery of Novel G-Protein Coupled Receptor (GPCR)-Targeted Therapies
From Tectonic Therapeutic
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today